^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    PhasED-Seq™ ctDNA assay

    Company:
    Foresight Diagnostics
    Type:
    Laboratory Developed Test
    Related tests:

    Details

    Evidence
    News
    Foresight CLARITY™, powered by PhasED-Seq™ technology, is a liquid-biopsy platform designed to confidently detect the presence of minimal residual disease (MRD) from circulating tumor DNA (ctDNA) with unprecedented sensitivity across multiple cancers.
    Method:
    ctDNA sequencing